Trials / Terminated
TerminatedNCT01747538
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Solution for subcutaneous injection |
| DRUG | Dose 1 gevokizumab | Solution for subcutaneous injection |
| DRUG | Dose 2 gevokizumab | Solution for subcutaneous injection |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-06-01
- First posted
- 2012-12-11
- Last updated
- 2016-07-12
Locations
115 sites across 22 countries: United States, Argentina, Armenia, Australia, Brazil, Canada, China, France, Germany, Greece, Israel, Italy, Mexico, Poland, Portugal, Russia, South Africa, Spain, Taiwan, Tunisia, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01747538. Inclusion in this directory is not an endorsement.